Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes
2013-05-31 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 31 May 2013 - Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes. Further information Media: Mike Rulis +45 3079 3573 [email protected] Ken Inchausti (US) +1 609 240 2919 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 41 / 2013
The release as fetched from its publisher. novonordisk.com ↗